Nektar Therapeutics (NKTR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 153 | 102 | 92 | 90 | 98 | 55 | 55 | 42 |
| Operating profit | $m | -131 | -131 | ||||||
| Net profit | $m | -444 | -524 | -368 | -276 | -119 | -164 | -157 | -138 |
| EPS reported | $ | -9.73 | -6.70 | ||||||
| Operating cashflow per share | $ | -12.36 | -8.08 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -12.37 | -8.09 | ||||||
| Free cash flow | $m | -209 | -234 | ||||||
| Net debt | $m | -162 | -627 | ||||||
| Book value equity | $m | 90 | - | ||||||
| Book value per share | $ | 5.32 | 31.23 | ||||||
| Number of shares | m | 16.87 | 33.05 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 7.94 | 2.34 | ||||||
| P/S LTM | x | 12.91 | 13.07 | ||||||
| P/FCF LTM | x | -3.42 | -3.05 | ||||||
| EV/EBITDA LTM | x | -6.18 | -6.30 | ||||||
| EV/Sales LTM | x | 15.34 | 39.09 | ||||||
| Earnings Yield LTM | % | -23.00% | -7.44% | ||||||
| FCF Yield | % | -29.26% | -32.81% | ||||||
| Quality | |||||||||
| ROE | % | -182.65% | -37.99% | ||||||
| ROIC | % | -52.82% | -12.53% | ||||||
| Operating margin | % | -2.37% | -2.40% | ||||||
| Gross margin | % | +100.00% | +61.19% | ||||||
| FCF/Sales | % | -377.83% | -428.75% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -43.89% | -44.54% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.40 | -1.72 | ||||||
| Net Debt/EBITDA | x | -0.98 | -0.29 | ||||||
| EBIT/Net interest | x | -4.99 | -196.44 | ||||||
| Net debt/market cap | % | +11.73% | +3.75% | ||||||
| Net debt/Equity | x | -1.80 | - | ||||||
| Gross debt/equity | x | 1.66 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free